Capecitabine for skin cancer prevention in solid organ transplant recipients

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 541-548

  Jirakulaporn, Tanawat ^a   Endrizzi, Bart ^b   Lindgren, Bruce ^c   Mathew, Josy ^a   Lee, Peter K ^b   Dudek, Arkadiusz Z ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Capecitabine; Chemoprevention; Immunosuppression; Skin cancer; Solid organ transplant recipients

Indexed keywords

CAPECITABINE;

ACTINIC KERATOSIS; ADULT; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GRAFT RECIPIENT; HAND FOOT SYNDROME; HEART TRANSPLANTATION; HUMAN; HYPERURICEMIA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SOLID ORGAN TRANSPLANT RECIPIENT; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; KERATOSIS, ACTINIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80051676703     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01348.x     Document Type: Article

References (27)

1. Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003: 41: 676.
2. Ativitavas T, Jirasiritham S, Ngorsakun P, Pipatpannawong K, Mavichak V. Malignancies in renal transplant patients: 15years experience in Thailand. Transplant Proc 2008: 40: 2403.
3. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28years' experience at a single centre. Transplant Proc 1997: 29: 828.
4. Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996: 61: 715.
5. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995: 33: 222.
6. Jensen P, Hansen S, Møller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999: 40: 177.
7. Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997: 44: 1172.
8. Guba M, Von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
9. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002: 73: 1565.
10. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
11. Ishikawa N, Tanabe K, Tokumoto T et al. Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single-center experience. Transplant Proc 2000: 32: 1907.
12. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993: 7: 431.
13. Carucci JA. Cutaneous oncology in organ transplant recipients: meeting the challenge of squamous cell carcinoma. J Invest Dermatol 2004: 123: 809.
14. Stasko T, Brown MD, Carucci JA et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004: 30: 642.
15. Bavinck JN, Tieben LM, Van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995: 13: 1933.
16. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002: 43: 269.
17. De Sévaux RG, Smit JV, De Jong EM, Van De Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003: 49: 407.
18. Euvrard S, Verschoore M, Touraine JL et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992: 340: 48.
19. Euvrard S, Kanitakis J, Claudy A. Topical retinoids for the management of dysplastic epithelial lesions. In: Thivolet J, Nicolas J-F, ed. Skin Diseases after Organ Transplantation. Montrouge: John Libbey Eurotext, 1998: 175.
20. Smit JV, Cox S, Blokx WA, Van De Kerhof PC, De Jongh GJ, De Jong EM. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002: 147: 816.
21. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005: 141: 985.
22. Ulrich C, Bichel J, Euvrard S et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007: 157: 25.
23. Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol 1990: 22: 905.
24. Sadek H, Azli N, Wendling JL et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990: 66: 1692.
25. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007: 156: 320.
26. Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005: 131: 300.
27. Sun JF, Wu RR, Norris C et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009: 3: 134.